AR085484A1 - ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA - Google Patents
ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINAInfo
- Publication number
- AR085484A1 AR085484A1 ARP120100945A ARP120100945A AR085484A1 AR 085484 A1 AR085484 A1 AR 085484A1 AR P120100945 A ARP120100945 A AR P120100945A AR P120100945 A ARP120100945 A AR P120100945A AR 085484 A1 AR085484 A1 AR 085484A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- epiregulin
- antibodies
- tgf
- heavy chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Los anticuerpos son útiles en el tratamiento de neuropatía diabética.Reivindicación 1: Un anticuerpo que se une a TGF-a y Epiregulina, caracterizado porque comprende una cadena ligera y una cadena pesada, en donde la cadena ligera comprende una región variable de cadena ligera (LCVR) y la cadena pesada comprende una región variable de cadena pesada (HCVR), en donde la LCVR comprende secuencias de aminoácido LCDR1, LCDR2, y LCDR3, y la HCVR comprende secuencias de aminoácido HCDR1, HCDR2, y HCDR3, en donde LCDR1 es SEC ID Nº 4, LCDR2 es SEC ID Nº 5, LCDR3 es SEC ID Nº 6, HCDR1 es SEC ID Nº 1, HCDR2 es SEC ID Nº 2, y HCDR3 es SEC ID Nº 3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161472338P | 2011-04-06 | 2011-04-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085484A1 true AR085484A1 (es) | 2013-10-02 |
Family
ID=45929050
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100945A AR085484A1 (es) | 2011-04-06 | 2012-03-22 | ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA |
| ARP210102953A AR123912A2 (es) | 2011-04-06 | 2021-10-25 | ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102953A AR123912A2 (es) | 2011-04-06 | 2021-10-25 | ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8613921B2 (es) |
| EP (1) | EP2694547B1 (es) |
| JP (1) | JP2014515743A (es) |
| KR (1) | KR101581517B1 (es) |
| CN (1) | CN103459423B (es) |
| AR (2) | AR085484A1 (es) |
| AU (1) | AU2012240508B2 (es) |
| BR (1) | BR112013023513A2 (es) |
| CA (1) | CA2832256C (es) |
| CY (1) | CY1116332T1 (es) |
| DK (1) | DK2694547T3 (es) |
| EA (1) | EA024921B1 (es) |
| ES (1) | ES2539503T3 (es) |
| HK (1) | HK1190410A1 (es) |
| HR (1) | HRP20150468T1 (es) |
| IL (1) | IL228101A0 (es) |
| ME (1) | ME02063B (es) |
| MX (1) | MX2013011596A (es) |
| PL (1) | PL2694547T3 (es) |
| PT (1) | PT2694547E (es) |
| RS (1) | RS54000B1 (es) |
| SG (1) | SG193452A1 (es) |
| SI (1) | SI2694547T1 (es) |
| TW (1) | TWI454481B (es) |
| UA (1) | UA110051C2 (es) |
| WO (1) | WO2012138510A1 (es) |
| ZA (1) | ZA201306813B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220054689A (ko) | 2019-10-15 | 2022-05-03 | 일라이 릴리 앤드 캄파니 | 재조합적으로 조작된, 리파제/에스테라제-결핍 포유동물 세포주 |
| TWI807338B (zh) * | 2020-06-26 | 2023-07-01 | 美商美國禮來大藥廠 | 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途 |
| KR102495473B1 (ko) * | 2020-10-06 | 2023-02-06 | 서울대학교병원 | 앰피레귤린을 유효성분으로 포함하는 안질환 치료용 조성물 |
| AR125902A1 (es) | 2021-05-21 | 2023-08-23 | Lilly Co Eli | Compuestos y métodos dirigidos a epirregulina |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5190858A (en) | 1989-02-01 | 1993-03-02 | Oncogene Science, Inc. | Monoclonal antibodies directed to epitopes of human transforming growth factor--α and uses thereof |
| CA2683109A1 (en) | 2006-10-11 | 2008-04-17 | Fusion Antibodies Limited | Combination therapy |
| JP5687822B2 (ja) | 2006-10-12 | 2015-03-25 | 中外製薬株式会社 | 抗ｅｒｅｇ抗体を用いる癌の診断および治療 |
| GB0807018D0 (en) * | 2008-04-17 | 2008-05-21 | Fusion Antibodies Ltd | Antibodies and treatment |
| WO2010137654A1 (ja) * | 2009-05-29 | 2010-12-02 | 株式会社未来創薬研究所 | Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物 |
-
2012
- 2012-03-22 AR ARP120100945A patent/AR085484A1/es active IP Right Grant
- 2012-03-23 TW TW101110200A patent/TWI454481B/zh not_active IP Right Cessation
- 2012-03-28 US US13/432,204 patent/US8613921B2/en active Active
- 2012-03-28 SG SG2013069075A patent/SG193452A1/en unknown
- 2012-03-28 RS RS20150321A patent/RS54000B1/en unknown
- 2012-03-28 EP EP12712049.1A patent/EP2694547B1/en active Active
- 2012-03-28 DK DK12712049T patent/DK2694547T3/en active
- 2012-03-28 UA UAA201311686A patent/UA110051C2/uk unknown
- 2012-03-28 BR BR112013023513A patent/BR112013023513A2/pt not_active IP Right Cessation
- 2012-03-28 WO PCT/US2012/030802 patent/WO2012138510A1/en active Application Filing
- 2012-03-28 JP JP2014503684A patent/JP2014515743A/ja not_active Ceased
- 2012-03-28 KR KR1020137025929A patent/KR101581517B1/ko active IP Right Grant
- 2012-03-28 ES ES12712049.1T patent/ES2539503T3/es active Active
- 2012-03-28 SI SI201230160T patent/SI2694547T1/sl unknown
- 2012-03-28 PT PT127120491T patent/PT2694547E/pt unknown
- 2012-03-28 MX MX2013011596A patent/MX2013011596A/es not_active Application Discontinuation
- 2012-03-28 ME MEP-2015-48A patent/ME02063B/me unknown
- 2012-03-28 CA CA2832256A patent/CA2832256C/en not_active Expired - Fee Related
- 2012-03-28 CN CN201280016829.XA patent/CN103459423B/zh not_active Expired - Fee Related
- 2012-03-28 PL PL12712049T patent/PL2694547T3/pl unknown
- 2012-03-28 AU AU2012240508A patent/AU2012240508B2/en not_active Ceased
- 2012-03-28 EA EA201370196A patent/EA024921B1/ru active IP Right Revival
-
2013
- 2013-08-22 IL IL228101A patent/IL228101A0/en unknown
- 2013-09-10 ZA ZA2013/06813A patent/ZA201306813B/en unknown
-
2014
- 2014-04-09 HK HK14103390.4A patent/HK1190410A1/xx unknown
-
2015
- 2015-04-17 CY CY20151100362T patent/CY1116332T1/el unknown
- 2015-05-04 HR HRP20150468TT patent/HRP20150468T1/hr unknown
-
2021
- 2021-10-25 AR ARP210102953A patent/AR123912A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20180604A1 (es) | Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana) | |
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| NZ603607A (en) | Cgrp antibodies | |
| PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| AR123912A2 (es) | ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| PE20171103A1 (es) | Anticuerpos heterodimericos que se unen a cd3 y cd38 | |
| PE20150159A1 (es) | Composiciones y metodos para anticuerpos que actuan sobre el factor p | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| EA035160B9 (ru) | Антитела к st2 и их применение | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| PE20091351A1 (es) | Anticuerpos humanizados especificos para el factor von willebrand | |
| PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |